BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28837442)

  • 1. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease.
    van de Peppel IP; Bertolini A; Jonker JW; Bodewes FAJA; Verkade HJ
    Curr Opin Pulm Med; 2017 Nov; 23(6):562-569. PubMed ID: 28837442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Manifestations of Cystic Fibrosis.
    Sakiani S; Kleiner DE; Heller T; Koh C
    Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Eldredge JA; Oliver MR; Ooi CY
    Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 5. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 6. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
    VanDevanter DR; Mayer-Hamblett N
    Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

  • 9. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.
    Mallea J; Bolan C; Cortese C; Harnois D
    Liver Transpl; 2019 Aug; 25(8):1265-1275. PubMed ID: 31102574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 12. Current Treatment Options for Cystic Fibrosis-Related Liver Disease.
    Staufer K
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver disease in patients with cystic fibrosis.
    Kamal N; Surana P; Koh C
    Curr Opin Gastroenterol; 2018 May; 34(3):146-151. PubMed ID: 29438119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis.
    Houwen RHJ; van der Woerd WL; Slae M; Wilschanski M
    Curr Opin Pulm Med; 2017 Nov; 23(6):551-555. PubMed ID: 28787381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease.
    Kitson MT; Kemp WW; Iser DM; Paul E; Wilson JW; Roberts SK
    Liver Int; 2013 May; 33(5):698-705. PubMed ID: 23432782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper.
    Bodewes FAJA; Freeman AJ; Weymann A; Debray D; Scheers I; Verkade HJ; Narkewicz MR
    J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):153-165. PubMed ID: 38291686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives.
    Debray D; Narkewicz MR; Bodewes FAJA; Colombo C; Housset C; de Jonge HR; Jonker JW; Kelly DA; Ling SC; Poynard T; Sogni P; Trauner M; Witters P; Baumann U; Wilschanski M; Verkade HJ
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):443-448. PubMed ID: 28753176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    Dana J; Debray D; Beaufrère A; Hillaire S; Fabre M; Reinhold C; Baumert TF; Berteloot L; Vilgrain V
    J Hepatol; 2022 Feb; 76(2):420-434. PubMed ID: 34678405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
    Sadler MD; Crotty P; Fatovich L; Wilson S; Rabin HR; Myers RP
    Can J Gastroenterol Hepatol; 2015 Apr; 29(3):139-44. PubMed ID: 25855877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.